Search Results
May 07, 2026, 09:00 ET Most Enterprise AI Is Built on a Foundation No One Has Measured
evaluation of twelve enterprise platforms across knowledge management, enterprise search, and business intelligence. Conducted by Dr. Anthony J. Rhem, PhD, the guide provides technology and business leaders with a framework to examine what lies beneath their AI strategy.
More news about: Bloomfire
May 07, 2026, 08:10 ET New national study published in The Permanente Journal shows physicians are changing their reasons for leaving clinical practice early
practice of medicine, we might uncover meaningful insights that will help us improve physician professional satisfaction and retention," said Sea Chen, MD, PhD, the paper's corresponding author. Chen works for the AMA in Chicago. The paper,
More news about: The Permanente Federation
May 07, 2026, 08:00 ET Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201
tumor-selective epitopes and intentionally engineer TCR bispecifics designed to engage them with high affinity and specificity," said Anthony Coyle, PhD, President and Head of Research and Development at Repertoire Immune Medicines. "Derived from our DECODE™ platform, RPTR-1-201 couples an epitope-specific
More news about: Repertoire Immune Medicines
May 07, 2026, 08:00 ET New findings suggest 5-MTHF is a viable alternative to folic acid during second and third trimester, supporting folate status while reducing excess folic acid in circulation
critical life stage when many individuals rely on supplements and place significant trust in their safety and efficacy," said Dr. Mastaneh Sharafi, PhD, RD and Senior Vice President of Science & Innovation at Ritual. "There are still major gaps in prenatal nutrition research, and we see a responsibility
More news about: Ritual
May 07, 2026, 08:00 ET Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
our pipeline as we advance Phase 1 dose-escalation studies for HWK-007 and HWK-016, with a third IND planned for HWK-206 mid-year," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "We remain focused on high quality execution as we build toward initial data anticipated in 1H 2027, with
More news about: Whitehawk Therapeutics, Inc.
May 07, 2026, 07:00 ET FARE Introduces Its Newest PSA, "Empower Yourself, Empower Each Other," Featuring Actor, Food Allergy Patient and FARE Volunteer Ambassador Joshua Jackson
food allergy and this PSA is an important step forward in that work. Impact begins with awareness but that isn't the finish line," said Sung Poblete, PhD, RN, CEO of FARE. "Real empowerment begins when you have the confidence and knowledge to ask important questions, explore your options, and seek an allergist's
More news about: FARE (Food Allergy Research & Education)
May 07, 2026, 07:00 ET Tetrous® Wins "Most Exciting New Product" Award at Shoulder 360™
complete the healing triad of (a) fixation, (b) structure and, now with Tetrous, (c) biology - leading to better outcomes for patients," said Bradley Patt, PhD, Co-founder, Director and CEO.About Tetrous, Inc.Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies
More news about: Tetrous
May 07, 2026, 07:00 ET Nitra Launches "Future of Care Initiative," Commits $20 Billion in Financing for Independent Medical Practices Across America
commitment to the doctors who are fighting to stay independent, and I am proud to help lead it."Dr. Subhransu K. Ray, MD, PhD is the senior partner at Bay Area Retina Associates and a fellowship-trained vitreoretinal surgeon who completed his training at the Massachusetts
More news about: Nitra
May 07, 2026, 03:00 ET Yatsen's $100 Million R&D Investment Wins Consumer Trust and Market Share
strategy encompasses three research centers across Shanghai, Guangzhou, and Toulouse, France, with over half of its R&D team holding master's or PhD degrees. The company maintains six joint research laboratories and more than 20 collaborative programs with prestigious institutions including Saint-Louis
More news about: Yatsen Holding Limited
May 06, 2026, 18:48 ET The Neuroscience of Leadership - A New Book Release by Fielding Press
The Neuroscience of Leadership by Fielding Graduate University alum Marcia Ruben, PhD, (ISBN-13: 979-8995988809; 281 pages; $26.95). The book weaves together proven leadership practices, neuroscience, complexity theory, adult development,
More news about: Fielding Graduate University
May 06, 2026, 14:35 ET Thomas Jefferson University Announces Major Academic Expansion to Lehigh Valley
Practitioner. Additional programs include a PhD in Nursing, an RN-to-BSN program, advanced certificates, and more — all pending accreditation.*"We are thrilled to expand our University's world-class academic experience to the Lehigh Valley," said Susan C. Aldridge, PhD, President of Thomas Jefferson University.
More news about: Thomas Jefferson University
May 06, 2026, 12:39 ET SOCOTEC Appoints Ivan Jelic, PhD, PE, as EVP to Strengthen Capabilities for Complex Projects
NEW YORK, May 6, 2026 /PRNewswire/ -- SOCOTEC US today announced the appointment of Ivan Jelic, PhD, PE, as Executive Vice President of its Technical Consulting & Advisory (TCA) practice, marking a key step in the firm's strategy to scale its
More news about: SOCOTEC
May 06, 2026, 11:58 ET ADLM announces 2026 award winners; celebrates achievements in laboratory medicine
Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory MedicineAlan Wu, PhD, DABCC, FACBSan Francisco General HospitalUniversity of California, San Francisco
More news about: Association for Diagnostics & Laboratory Medicine (ADLM)
May 06, 2026, 10:45 ET Vilcek Foundation mourns Marica Vilcek, cofounder, art historian, and philanthropist
she earned bachelor's and master's degrees in art history, and in 1959, was awarded a Candidate of Sciences degree in art history, the equivalent of a PhD.Vilcek's thoughtful appreciation and meticulous work earned the young art historian a prestigious appointment with the Slovak National Gallery
More news about: The Vilcek Foundation
May 06, 2026, 09:05 ET Debut and Oterra partner to develop and scale biotech alternative to Red 40 for food and beverage
alternatives.""We're excited to fast-track the commercialization of natural red alternatives from precision fermentation with Oterra," said Joshua Britton, PhD, Founder and CEO of Debut. "Biotech offers clear advantages that align with evolving market demand. Its adoption in the food and beverage industry is
More news about: Oterra
May 06, 2026, 09:00 ET The Next Frontier in Gut Health is Man's Best Friend. New Study on Breakthrough Postbiotic from Kingdom Shows Improved Stool Quality in Dogs
wellness category where visible benefits are essential."The bar for evidence in pet nutrition has been far too low for too long," said Ravi Sheth, PhD, co-founder and chief scientific officer at Kingdom. "With two peer-reviewed publications now validating real, measurable outcomes with Superculture®
More news about: Kingdom
May 06, 2026, 09:00 ET Privacy Capability Struggles to Keep Pace With AI Adoption, TrustArc Annual Global Survey Finds
out in this year's data is the widening divide between more mature privacy programs and those still developing their capabilities," said Gary Edwards, PhD, Head of Research and CEO of Golfdale Consulting. "That gap reflects how effectively organizations operationalize privacy in practice, particularly as
More news about: TrustArc
May 06, 2026, 09:00 ET Vori Raises $22M to Build the Operating System for the World's Grocery Stores
grounded in relentless execution and Brandon's team at Vori is one of them. Before writing a single line of code, the team spent four years earning a PhD in grocery, going store to store, learning the rhythms, workflows, and economics that no outside company had bothered to understand."For more
More news about: Vori
May 06, 2026, 08:30 ET Logosynthesis International Association Announces New President to Lead Next Phase of Strategic Development
-- The Logosynthesis® International Association (LIA™) announced the appointment of Regina Thiergardt, PhD, of Switzerland, as President, effective March 25, 2026. She succeeds Heike Rudolf von Rohr, PhD, who completed her three-year term as President after leading significant strategic development within
More news about: Logosynthesis® International Association
May 06, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Announces Appointment of Aimee Johnson as Chief Marketing Officer
treatments."Aimee brings an exceptional track record of marketing iconic brands and connecting innovation to real-world impact," said Dr. Karen R. Knudsen, MBA, PhD, CEO of PICI. "Her experience leading high-performing marketing organizations, combined with her ability to translate complex ideas into compelling narratives,
More news about: Parker Institute for Cancer Immunotherapy
May 06, 2026, 05:00 ET American Council Of Learned Societies Announces 2026 Luce/ACLS Early Career Fellowships and Travel Grants in China Studies
Thirteen Luce/ACLS Travel Grants in China Studies provide $5,000 for graduate students in PhD programs and non-tenure-track scholars at any career stage to visit research sites in China or China studies-related collections and archives anywhere
More news about: American Council of Learned Societies
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
dry age related macular degeneration," said Sunil Patel, MD, PhD, a principal investigator of the study."We are delighted to present the compelling Phase II data to the global ophthalmology community at ARVO," said Fred Ouyang, PhD, Chief Technology Officer of MingMed Biotechnology. "QA102 represents
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
dry age related macular degeneration," said Sunil Patel, MD, PhD, a principal investigator of the study."We are delighted to present the compelling Phase II data to the global ophthalmology community at ARVO," said Fred Ouyang, PhD, Chief Technology Officer of MingMed Biotechnology. "QA102 represents
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology präsentiert auf der Tagung der Association for Research in Vision and Ophthalmology (ARVO) 2026 positive Phase-II-Daten zum oralen Wirkstoff QA102 für die Behandlung der intermediären altersbedingten Makuladegeneration (AMD)
Makuladegeneration betroffen sind", sagte Dr. med. Sunil Patel, PhD, einer der Leiter der Studie.„Wir freuen uns sehr, der globalen Augenheilkunde-Fachwelt auf der ARVO diese überzeugenden Phase-II-Daten präsentieren zu können", sagte Dr. Fred Ouyang, PhD, Chief Technology Officer von MingMed Biotechnology.
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology présente des données positives de phase II sur le QA102 oral pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) intermédiaire lors de la réunion 2026 de l'Association for Research in Vision and Ophthalmology (ARVO)
a déclaré le docteur Sunil Patel, PhD, l'un des principaux investigateurs de l'étude.« Nous sommes ravis de présenter les données convaincantes de la phase II à la communauté ophtalmologique mondiale lors de la réunion de l'ARVO », a déclaré Fred Ouyang, PhD, directeur de la technologie chez MingMed
More news about: MingMed Biotechnology Co., Ltd